--- title: "Denali Therapeutics (DNLI) stock: news and investor profile" url: "https://aibio.space/companies/denali-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Denali Therapeutics Inc. (NASDAQ: DNLI), United States. The directory classifies it as Biotechnology." --- DNLI Denali Therapeutics Inc. NASDAQ · United States # Denali Therapeutics (DNLI) news Top story · Jul 28, 2026 · SEC filing 8-K ## [Denali Therapeutics completes an acquisition or sale of assets](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm) Pursuant to the PRV Transfer Agreement, the Company received gross proceeds of $195.0 million from the buyer upon the closing of the Sale. Source: [8-K filed Jul 28, 2026 on SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm) ## Latest Denali Therapeutics news We have not published a story on Denali Therapeutics yet. When there is news, it will appear here. ## Denali Therapeutics at a glance - **Ticker**: DNLI - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $710.5 million ### Related companies - [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) NYSE: RCUS - [Pliant Therapeutics](https://aibio.space/companies/pliant-therapeutics/) NASDAQ: PLRX - [Taysha Gene Therapies](https://aibio.space/companies/taysha-gene-therapies/) NASDAQ: TSHA - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) NASDAQ: ADPT - [GlobeStar Therapeutics](https://aibio.space/companies/globestar-therapeutics/) OTC: GSTC - [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) NASDAQ: VIR - [Galectin Therapeutics](https://aibio.space/companies/galectin-therapeutics/) NASDAQ: GALT ### Also on NASDAQ - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) PRLD - [Entera Bio](https://aibio.space/companies/entera-bio/) ENTX - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) TGTX - [Celldex Therapeutics](https://aibio.space/companies/celldex-therapeutics/) CLDX - [SeaStar Medical Holding](https://aibio.space/companies/seastar-medical/) ICU - [enVVeno Medical](https://aibio.space/companies/envveno-medical/) NVNO ## What Denali Therapeutics does Denali Therapeutics is a biopharmaceutical company that aims to deliver biotherapeutics to the brain and the rest of the body. Its proprietary TransportVehicle (TV) technology is designed to cross the blood-brain barrier, carrying large molecules such as enzymes, oligonucleotides and antibodies to tissues after systemic administration. The company builds three TV franchises: Enzyme TV (ETV), Oligonucleotide TV (OTV) and Antibody TV (ATV). Its programs target rare diseases such as lysosomal storage disorders and common diseases such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for mucopolysaccharidosis II (MPS II), also called Hunter syndrome. The biologics license application for tividenofusp alfa is under priority review for accelerated approval by the FDA, with a PDUFA target action date of April 5, 2026. The clinical development portfolio also includes DNL126 for MPS IIIA, DNL593 for frontotemporal dementia-granulin, DNL628 for Alzheimer's disease and DNL952 for Pompe disease. | Product or program | What it is | Stage | |---|---|---| | tividenofusp alfa | Enzyme TV-enabled therapy for MPS II (Hunter syndrome) | under priority review | | DNL126 | TV-enabled candidate for MPS IIIA (Sanfilippo syndrome type A) | clinical development | | DNL593 | TV-enabled candidate for frontotemporal dementia-granulin | clinical development | | DNL628 | Oligonucleotide TV candidate for Alzheimer's disease | clinical development | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm). ## Denali Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | [$0](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | | Research and development | [$418.8 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | [$396.4 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | | Net income (loss) | [-$512.5 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | [-$422.8 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | | Cash from operations | [-$412.6 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | [-$347.7 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | | Cash and equivalents | [$205.3 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000097/) | [$175.0 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | | Short-term investments | [$662.6 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000097/) | [$657.4 million](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $201.5 million, plus short-term investments of $508.9 million, $710.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Denali Therapeutics What is the ticker symbol of Denali Therapeutics? Denali Therapeutics Inc. trades under the ticker DNLI on NASDAQ. Where is Denali Therapeutics listed? Denali Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:4DN; LS:A2H9G8; LSX:A2H9G8. What is the SEC CIK of Denali Therapeutics? The SEC Central Index Key (CIK) for Denali Therapeutics Inc. is 1714899. Its filings are on SEC EDGAR. How many shares does Denali Therapeutics have outstanding? 159,847,403 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Denali Therapeutics listed under? Our directory records Denali Therapeutics Inc. under United States. What does Denali Therapeutics do? Our directory classifies Denali Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Denali Therapeutics? The ISIN recorded for Denali Therapeutics Inc. is US24823R1059. Does aibio.space cover Denali Therapeutics? aibio.space lists Denali Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Denali Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Denali Therapeutics develop? Denali Therapeutics is a biopharmaceutical company that aims to deliver biotherapeutics to the brain and the rest of the body. Its proprietary TransportVehicle (TV) technology is designed to cross the blood-brain barrier, carrying large molecules such as enzymes, oligonucleotides and antibodies to tissues after systemic administration. What is tividenofusp alfa from Denali Therapeutics? tividenofusp alfa: Enzyme TV-enabled therapy for MPS II (Hunter syndrome) Stage: under priority review. What is DNL126 from Denali Therapeutics? DNL126: TV-enabled candidate for MPS IIIA (Sanfilippo syndrome type A) Stage: clinical development. What was Denali Therapeutics's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Denali Therapeutics profitable? Denali Therapeutics Inc. reported a net loss of $512.5 million for the fiscal year ended Dec 31, 2025, and used $412.6 million of cash in operations, per its annual report to the SEC. How much does Denali Therapeutics spend on research and development? $418.8 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Denali Therapeutics Members talk about Denali Therapeutics (DNLI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Denali Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-28 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm) 2. 2026-04-03 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/ex9912026pressrelease4326.htm) 3. 2026-03-31 Financings Reported a financing. SEC Form 8-K (Items 2.03,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000036/dnli-20260327.htm) 4. 2026-01-06 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000004/ex9912026outlookpressrelea.htm) 5. 2025-12-09 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1714899/000162828025056085/denaliprosupp424b5prelim.htm) 6. 2025-06-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/dnli-20250603.htm) 7. 2025-02-27 Financings Reported a financing. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1714899/000162828025008647/denalitherapeuticss-3asrx2.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DNLI on TradingView](https://www.tradingview.com/symbols/NASDAQ-DNLI/). ## SEC filings and registration - **SEC name**: Denali Therapeutics Inc. - **CIK**: 1714899 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: DNLI (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: (650) 866-8547 - **Shares outstanding**: 159,847,403 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000097/dnli-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000096/dnli-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000086/dnli-20260727.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/dnli-20260612.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000074/dnli-20260603.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000070/dnli-20260521.htm) filed 2026-05-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000064/dnli-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/dnli-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001714899), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Denali Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DNLI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Denali Therapeutics Inc. - **Ticker**: DNLI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US24823R1059 - **Other listed symbols**: GETTEX:4DN; LS:A2H9G8; LSX:A2H9G8 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DNLI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/denali-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Denali Therapeutics (DNLI) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/denali-therapeutics/